• PDGF-BB Workflow for Pulmonary Hypertension Research

  2026-08-12

  Build reproducible vascular-remodeling assays with murine recombinant PDGF-BB as a defined mitogenic stimulus, then connect proliferation readouts to hypoxia-associated metabolic remodeling. This workflow combines dose-response design, receptor-aware controls, and mitochondrial phenotyping for stronger pulmonary hypertension experiments.

• Shh–Fgf Control of Urethral Groove Development

  2026-08-11

  A 2025 Cells study identifies differential Shh, Fgf10, and Fgfr2 expression as a developmental explanation for why guinea pigs form an open urethral groove whereas mice form a tubular urethra without an equivalent groove. By combining comparative gene-expression analysis with genital-tubercle organ culture and pathway perturbation, the work links signaling intensity to species-specific preputial and urethral morphogenesis.

• ABT-888 (Veliparib) Workflow for DNA Repair Studies

  2026-08-11

  ABT-888 (Veliparib) combines strong PARP1/2 target engagement with practical utility in chemotherapy, radiation, and DNA damage response workflows. This guide translates colorectal cancer and MSI model evidence into reproducible assay design while showing why recent leukemia screening data argue for biomarker-aware combination testing.

• Radioiodinated Balsalazide for UC Imaging in Mice

  2026-08-10

  Sanad and colleagues developed and evaluated radioiodinated balsalazide as a colon-targeted tracer for ulcerative colitis in mice. The optimized labeling workflow produced a stable radiotracer with strong uptake in ulcerated colon, supporting preclinical imaging and biodistribution studies while leaving important questions about receptor specificity and clinical translation unresolved.

• BRD4–RAC1 Co-Targeting in Breast Cancer

  2026-08-09

  The reference study shows that simultaneous inhibition of BRD4 and RAC1 suppresses growth, stemness, migration, and tumorigenesis across luminal-A, HER2-positive, and triple-negative breast cancer models. Its mechanistic contribution is the identification of a c-MYC–G9a–FTH1 pathway and HDAC1-associated chromatin response that connect dual pathway inhibition to autophagy, senescence, and reduced tumor growth.

• SLC2A5 Fructose Metabolism in Primary CNS Lymphoma

  2026-08-08

  This Advanced Science study uses single-cell RNA and B-cell receptor profiling to identify SLC2A5-mediated fructose utilization as a metabolic adaptation in primary central nervous system lymphoma. The findings connect glucose-poor, hypoxic tumor microenvironments with lymphoma growth, macrophage support, and T-cell dysfunction, while functional experiments nominate SLC2A5 as a potential therapeutic vulnerability.

• LXR Signaling and Alveolar Cell Survival in BPD

  2026-08-07

  Ma et al. identify disrupted cholesterol homeostasis and reduced LXR signaling as a mechanistic link between hyperoxia and alveolar epithelial cell apoptosis in bronchopulmonary dysplasia. Using preterm infant samples, neonatal rats, and MLE12 cells, the study shows that LXR activation is associated with reduced cholesterol accumulation, oxidative stress, mitochondrial dysfunction, and epithelial injury.

• Cyclopamine in Translational Oncology: Beyond Pathway Inhibi

  2026-08-07

  Explore how Cyclopamine, a potent Hedgehog signaling inhibitor, is reshaping translational cancer research by enabling mechanistic dissection, advanced apoptosis studies, and protocol refinement. This article uniquely connects molecular insights with modern assay design.

• AG-490 (Tyrphostin B42): JAK2/EGFR Inhibition in Cancer Rese

  2026-08-06

  AG-490 (Tyrphostin B42) is a selective JAK2 and EGFR inhibitor with nanomolar to micromolar potency. It modulates the JAK-STAT and MAPK pathways, supporting cancer and immunopathological research. The compound is insoluble in water but offers robust signaling pathway inhibition, enabling dissection of tumor microenvironment mechanisms.

• AO/PI Staining Solution: Precision Cell Viability for Advanc

  2026-08-06

  Explore how the AO/PI Staining Solution enables high-precision live/dead cell discrimination in complex apoptosis and inflammation research. Discover novel workflow insights and protocol optimization strategies that extend beyond standard fluorescent DNA dye assays.

• Influenza Hemagglutinin (HA) Peptide: Enabling Quantitative

  2026-08-05

  Explore how the Influenza Hemagglutinin (HA) Peptide advances quantitative protein tagging and exosome pathway studies. Uncover mechanistic insights, protocol parameters, and strategic distinctions for leveraging this HA tag peptide in high-precision molecular biology.

• Purmorphamine: Smoothened Agonist for Advanced Cell Modulati

  2026-08-05

  Purmorphamine stands out as a precise Smoothened agonist, enabling targeted Hedgehog pathway activation in bone, neural, and sensory research. This guide distills protocol optimizations, troubleshooting, and novel applications, including breakthrough insights from insect models.

• Pentoxifylline (SKU C3816): Reliable Protocols for Inflammat

  2026-08-04

  This article guides biomedical researchers through real-world laboratory challenges where Pentoxifylline (SKU C3816) enhances assay reliability, experimental reproducibility, and data interpretation. Drawing on peer-reviewed evidence, it details protocol parameters, troubleshooting, and product selection criteria, positioning APExBIO’s Pentoxifylline as a preferred resource for sensitive inflammation and cell viability studies.

• Annexin V-FITC/PI Apoptosis Assay Kit: Technical Use Guide

  2026-08-04

  The Annexin V-FITC/PI Apoptosis Assay Kit enables rapid, stage-specific discrimination of apoptosis and necrosis using a fluorescence-based workflow. It is best deployed for research applications requiring accurate early apoptosis detection by phosphatidylserine externalization and membrane integrity assessment. The kit is inappropriate for diagnostic or clinical use and its performance depends on adherence to protocol and proper sample handling.

• Cyclopamine as a Hedgehog Signaling Inhibitor: Applied Proto

  2026-08-03

  Cyclopamine delivers targeted Hedgehog pathway inhibition for diverse research needs, from cancer models to developmental biology. This article spotlights actionable workflows, troubleshooting insights, and the translational edge of APExBIO’s Cyclopamine in experimental designs.

8030 records 5/536 page Previous Next 12345 下5页 Last page